prikaz prve stranice dokumenta Farmakoterapija šećerne bolesti tipa 2
  Download
PDF 2.11 MB
Scientific paper - Review paper
Farmakoterapija šećerne bolesti tipa 2
Farmaceutski glasnik, 75 (2019), 9; 629-664. urn:nbn:hr:163:607971
Cvek, Josipa; Mirošević Skvrce, Nikica; Vučić, Katarina; Andrić, Adriana; Ortner Hadžiabdić, Maja

Cite this document

Cvek, J., Mirošević Skvrce, N., Vučić, K., Andrić, A. & Ortner Hadžiabdić, M. (2019). Farmakoterapija šećerne bolesti tipa 2. Farmaceutski glasnik, 75. (9), 629-664. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:607971

Cvek, Josipa, et al. "Farmakoterapija šećerne bolesti tipa 2." Farmaceutski glasnik, vol. 75, no. 9, 2019, pp. 629-664. https://urn.nsk.hr/urn:nbn:hr:163:607971

Cvek, Josipa, Nikica Mirošević Skvrce, Katarina Vučić, Adriana Andrić and Maja Ortner Hadžiabdić. "Farmakoterapija šećerne bolesti tipa 2." Farmaceutski glasnik 75, no. 9 (2019): 629-664. https://urn.nsk.hr/urn:nbn:hr:163:607971

Cvek, J., et al. (2019) 'Farmakoterapija šećerne bolesti tipa 2', Farmaceutski glasnik, 75(9), pp. 629-664. Available at: https://urn.nsk.hr/urn:nbn:hr:163:607971 (Accessed 04 December 2024)

Cvek J, Mirošević Skvrce N, Vučić K, Andrić A, Ortner Hadžiabdić M. Farmakoterapija šećerne bolesti tipa 2. Farmaceutski glasnik [Internet]. 2019 [cited 2024 December 04];75(9):629-664. Available at: https://urn.nsk.hr/urn:nbn:hr:163:607971

J. Cvek, N. Mirošević Skvrce, K. Vučić, A. Andrić and M. Ortner Hadžiabdić, "Farmakoterapija šećerne bolesti tipa 2", Farmaceutski glasnik, vol. 75, no. 9, pp. 629-664, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:607971. [Accessed: 04 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Farmakoterapija šećerne bolesti tipa 2
AuthorJosipa Cvek
AuthorNikica Mirošević Skvrce
AuthorKatarina Vučić
AuthorAdriana Andrić
AuthorMaja Ortner Hadžiabdić
Author's institutionUniversity of Zagreb
Faculty of Pharmacy and Biochemistry
(Centre for applied pharmacy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Pharmacy
Pharmacy
Abstract (english)
Although normoglycemia for most diabetic patients is hard to achieve, any therapy that contributes to glucose regulation may delay the development of complications and improve the quality of life for the patients. While therapy of type 1 diabetes is primarily focused on maintaining good glycemic control, in patients with type 2 diabetes attention should also be paid to the treatment of comorbidities. Polypharmacy in type 2 diabetes increases the risk of adverse drug reactions (ADRs) and negatively affects patient adherence. In order to attain optimal treatment outcomes, an individualized approach with awareness of possible ADRs should be applied in the pharmacotherapy of diabetic patients. The risks of long-term use of new antidiabetics are not fully clarified and spontaneous reporting of their suspected ADRs resulted in a series of safety signals in post-approval phase. This paper reviewed the available literature on the pharmacotherapeutic options for the treatment of type 2 diabetes and lists current knowledge on the safety profile of antidiabetic drugs.
Keywords (croatian)
Languagecroatian
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - domestic
Publication versionPublished version
Journal titleFarmaceutski glasnik
Numberingvol. 75, no. 9, pp. 629-664
p-ISSN0014-8202
URN:NBNurn:nbn:hr:163:607971
Publication2019
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-06-16 12:32:53